RCAT
Red Cat Holdings, Inc.
RCAT lost money over the past year, so it has no meaningful PE right now.
RCAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
RCAT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
RCAT PE Valuation
RCAT has no meaningful PE right now: it lost money over the past year.
RCAT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect RCAT's revenue to grow and its profitability to improve, with its earnings holding steady.
RCAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.79 | +$0.04 |
| Q1 2026 | -$0.68 | +$0.16 |
| Q1 2023 | -$0.38 | -$0.07 |
| Q4 2022 | -$0.33 | +$0.27 |
| Q3 2022 | -$0.26 | +$0.33 |
| Q2 2022 | -$0.24 | +$0.32 |
RCAT lost $0.79 per share over the past year, about the same as its loss the year before.
RCAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $20.2M | +527% |
| Q1 2026 | $15.5M | +849% |
| Q4 2025 | $26.2M | +1866% |
| Q3 2025 | $9.6M | +529% |
| Q2 2025 | $3.2M | +16% |
| Q1 2025 | $1.6M | -74% |
| Q4 2024 | $1.3M | -77% |
| Q4 2024 | $1.5M | -61% |
RCAT's revenue has grown year over year for five quarters in a row: $20M last quarter, up 527% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -191% | +202 points |
| Q1 2026 | -176% | +589 points |
| Q4 2025 | -91% | +616 points |
| Q3 2025 | -182% | +687 points |
| Q2 2025 | -393% | +54 points |
| Q1 2025 | -766% | -647 points |
| Q4 2024 | -707% | -631 points |
| Q4 2024 | -869% | -753 points |
RCAT's operating margin was −191% last quarter, up 202 points from the same quarter a year ago.
RCAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$52.6M | -$39.4M |
| Q1 2026 | -$38.7M | -$22.5M |
| Q4 2025 | -$41.9M | -$25.7M |
| Q3 2025 | -$24.5M | -$14.4M |
| Q2 2025 | -$13.2M | -$10.8M |
| Q1 2025 | -$16.2M | -$13.8M |
| Q4 2024 | -$16.1M | -$12M |
| Q4 2024 | -$10.2M | -$5.7M |
RCAT has burned cash in almost every quarter: −$158M over the past year, against −$56M the year before.
RCAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +13% | +16M shares |
| 1 year | +50% | +45.6M shares |
| 3 years | +146% | +81.2M shares |
| 5 years | +302% | +103M shares |
| Available history | +709% | +120M shares |
RCAT has 137M diluted shares, up 50% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
RCAT Net Leverage
RCAT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RCAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.5 | Neutral |
| Stochastic | 7.9 | Oversold |
RCAT's weekly RSI is 32 (neutral) and its Stochastic is 8 (oversold).
RCAT PE vs Technology Sector
RCAT has no meaningful PE right now: it lost money over the past year.
RCAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.07 | 22% below |
| 20 week MA | $7.21 | 45% below |
| 50 week MA | $9.91 | 60% below |
| 100 week MA | $9.20 | 57% below |
| 200 week MA | $5.43 | 27% below |
RCAT is in a downtrend: it's below all five of its weekly moving averages, and 27% below its 200-week average.
RCAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.28 | $1.75 | +37% |
| 2021 | $1.75 | $2.18 | +25% |
| 2022 | $2.18 | $0.77 | -65% |
| 2023 | $0.77 | $0.88 | +14% |
| 2024 | $0.88 | $12.3 | +1293% |
| 2025 | $12.3 | $8.30 | -32% |
| 2026 YTD | $8.30 | $3.94 | -53% |
RCAT's yearly returns have swung widely, from +1293% in 2024 to −65% in 2022. It's down 53% so far in 2026.